Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)

BACKGROUND: Heterozygous familial hypercholesterolemia (HeFH) is largely underdiagnosed and undertreated in China where few patients achieved recommended target levels of low density lipoprotein cholesterol (LDL-C). We conducted the first randomized, placebo-controlled clinical trial in Chinese pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Meng, He, Yongming, Zhao, Wang, Han, Xuebin, Zhao, Guoyan, Ma, Xueping, Qiao, Ping, Shi, Dongmei, Liu, Yuyang, Han, Wei, An, Pei, Li, Haoyu, Yan, Shuling, Ma, Qingyang, Deng, Huan, Qian, Lei, Zhou, Yujie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976471/
https://www.ncbi.nlm.nih.gov/pubmed/36855099
http://dx.doi.org/10.1186/s12916-023-02797-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976471/
https://www.ncbi.nlm.nih.gov/pubmed/36855099
http://dx.doi.org/10.1186/s12916-023-02797-8

Ejemplares similares